Navidea Bio +26% premarket on Lymphoseek patent extension [Seeking Alpha]
Cardinal Health, Inc. (CAH)
Last cardinal health, inc. earnings: 2/6 06:55 am
Check Earnings Report
US:NYSE Investor Relations:
ir.cardinalhealth.com/home
Company Research
Source: Seeking Alpha
Healthcare | On the Move Navidea Bio +26% premarket on Lymphoseek patent extension Mar. 20, 2020 7:37 AM ET Navidea Biopharmaceuticals... (NAVB) Mamta Mayani Navidea Biopharmaceuticals (NYSEMKT: extend the duration This Certificate was based on the FDA recommendation under the Hatch-Waxman Act for patent term lost in regulatory review. This patent claims and protects Lymphoseek (technetium [Tc 99m] tilmanocept) and has been exclusively licensed with varying geographical and medical indication coverages to Cardinal Health and Navidea. The patent extension will permit both the companies to extend their exclusive rights to manufacture and commercialize Lymphoseek until 2025. See all stocks on the move » Now read: Daily Insider Ratings Round Up 2/19/20 »
Show less
Read more
Impact Snapshot
Event Time:
CAH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAH alerts
High impacting Cardinal Health, Inc. news events
Weekly update
A roundup of the hottest topics
CAH
News
- Cardinal Health (NYSE:CAH) Has Affirmed Its Dividend Of $0.5056 [Yahoo! Finance]Yahoo! Finance
- Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2025 on January 30PR Newswire
- Baltimore Mayor Scott shares draft of plan to address opioid crisis, manage settlement funds Mayor Brandon Scott released a draft of the city's plan to address the opioid crisis Wednesday, in keeping with an executive order established in August 2024 to Acquire Media Monitor
- Cardinal Health, Inc. (NYSE: CAH) had its price target raised by analysts at Morgan Stanley from $127.00 to $136.00. They now have an "overweight" rating on the stock.MarketBeat
- Intelliguard Strengthens Leadership and Launches Client Excellence Organization to Drive Growth and Customer Success [Yahoo! Finance]Yahoo! Finance
CAH
Earnings
- 11/1/24 - Beat
CAH
Sec Filings
- 12/9/24 - Form 8-K
- 12/3/24 - Form 4
- 12/3/24 - Form 4
- CAH's page on the SEC website